Xencor's Ultomiris Outlook Revision May Pressure ALXN Revenue
Xencor Inc. is revising its revenue forecasts for Ultomiris royalties, indicating potential declines in royalties tied to Alexion Pharmaceuticals’ key drug. This alteration could suggest reduced future sales and revenue expectations for ALXN, leading to heightened investor scrutiny and market volatility.
View signal analysis